{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:12:13Z","timestamp":1777421533652,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2481,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:p>\n                    Tegaserod, a potent partial agonist of the serotonin 5\u2010HT\n                    <jats:sub>4<\/jats:sub>\n                    receptor, is used to treat women with constipation\u2010predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.\n                  <\/jats:p>","DOI":"10.1592\/phco.25.4.620.61032","type":"journal-article","created":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T05:52:19Z","timestamp":1118641939000},"page":"620-625","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tegaserod\u2010Associated Ischemic Colitis"],"prefix":"10.1002","volume":"25","author":[{"given":"John K.","family":"DiBaise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-12-1009"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.272"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05657-5"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01103.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01449.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70251-4"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)00520-6"},{"key":"e_1_2_1_10_2","first-page":"182","article-title":"The endoscopy corner: reversible ischemic colitis\u2014correlation of colonoscopic and pathologic changes","volume":"72","author":"Forde KA","year":"1979","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199706000-00011"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)00519-X"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609051996"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1994.tb01563.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04097.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.21436.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30192.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01347.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21177"},{"key":"e_1_2_1_20_2","unstructured":"GlaxoSmithKline.Lotronex (alosetron hydrochloride) tablets: Briefing document for the joint gastrointestinal drugs advisory committee and drug safety and risk management committee. Available fromhttp:www.fda.govohrmsdocketsac02briefing3848B1_02_FDA20Lotronex.pdf. AccessedFebruary 4 2005."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07418.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01903.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)04840-2"},{"key":"e_1_2_1_24_2","first-page":"A41","article-title":"Patients with irritable bowel syndrome have a high\u2010risk of developing ischemic colitis [abstr]","volume":"126","author":"Singh G","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26046"},{"key":"e_1_2_1_26_2","volume-title":"Data on file","author":"Novartis Pharmaceuticals.","year":"2004"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392512"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00009"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2036.1999.00002.x-i2","article-title":"Roles played by 5\u2010hydroxytryptamine in the physiology of the bowel","volume":"13","author":"Gershon MD.","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.013"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.17.1946"},{"key":"e_1_2_1_33_2","first-page":"A42","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS\u2010D): efficacy and safety in a 6 month global study [abstr]","volume":"126","author":"Bradette M","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_1_34_2","volume-title":"Zelnorm (tegaserod maleate) package insert","author":"Novartis Pharmaceuticals.","year":"2004"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80736-9"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/23.2.117"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.25.4.620.61032","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.25.4.620.61032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:05:24Z","timestamp":1761066324000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.25.4.620.61032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1592\/phco.25.4.620.61032"],"URL":"https:\/\/doi.org\/10.1592\/phco.25.4.620.61032","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}